Cassava Sciences, Inc. (SAVA) financial statements (2021 and earlier)

Company profile

Business Address 7801 N CAPITAL OF TEXAS HIGHWAY
AUSTIN, TX 78731
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:94232010193141
Cash and cash equivalents94232010173141
Short-term investments    2  
Other undisclosed cash, cash equivalents, and short-term investments      (0)
Other current assets0000000
Other undisclosed current assets      0
Total current assets:94232011193241
Noncurrent Assets
Operating lease, right-of-use asset0 
Property, plant and equipment0000000
Other noncurrent assets  00 00
Other undisclosed noncurrent assets 0     
Total noncurrent assets:0000000
TOTAL ASSETS:94232011193241
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2111131
Accounts payable1000010
Accrued liabilities110001 
Employee-related liabilities0000011
Other liabilities00     
Other undisclosed current liabilities00    0
Total current liabilities:2111131
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0 
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities:0      
Total liabilities:2111131
Stockholders' equity
Stockholders' equity attributable to parent92222010192940
Common stock0000000
Additional paid in capital267191184167164160157
Accumulated other comprehensive income      0
Accumulated deficit(175)(169)(164)(157)(145)(131)(116)
Total stockholders' equity:92222010192940
TOTAL LIABILITIES AND EQUITY:94232011193241

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(6)(5)(7)(12)(15)(14)(12)
Operating loss:(6)(5)(7)(12)(15)(14)(12)
Loss from continuing operations before equity method investments, income taxes:(6)(5)(7)(12)(15)(14)(12)
Other undisclosed income from continuing operations before income taxes     00
Net loss:(6)(5)(7)(12)(15)(14)(12)
Other undisclosed net income attributable to parent00000  
Net loss available to common stockholders, diluted:(6)(5)(7)(12)(15)(14)(12)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(6)(5)(7)(12)(15)(14)(12)
Other comprehensive loss     (0) 
Comprehensive loss:(6)(5)(7)(12)(15)(14)(12)
Other undisclosed comprehensive income, net of tax, attributable to parent   00  
Comprehensive loss, net of tax, attributable to parent:(6)(5)(7)(12)(15)(14)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: